Brunangelo Falini MD profile image
Brunangelo Falini, MD
Scientific Advisory Board Member
  • Head of the Institute of Hematology and Bone Marrow Transplantation, University of Perugia, Perugia, Italy

Brunangelo Falini, M.D., is Professor of Hematology at the University of Perugia, Perugia, Italy. He received an M.D. degree and completed his residency in Internal Medicine at the University of Perugia. Then, he trained (1980-1981) with Robert J. Lukes on the immunological classification of human lymphomas at USC, Los Angeles, and worked (1982-1984) with David Y. Mason on the generation of monoclonal antibodies against lymphoma- and leukemia-associated antigens at Oxford University.

During his scientific carrier, he made important contributions in the field of lymphomas and leukemias by generating novel monoclonal antibodies directed against proteins encoded by genes involved in chromosomal translocations, by contributing to develop the modern classifications of lympho-hemopoietic neoplasms (REAL and WHO), and by applying in 1992 the first anti-CD30 immunotoxin for the therapy of refractory/relapsed Hodgkin lymphoma.

In the past 15 years, Dr. Falini made the seminal discoveries of nucleophosmin (NPM1) mutations in acute myeloid leukemia and BRAFV600E mutation in hairy cell leukemia. By discovering NPM1 mutations, Dr. Falini not only identified a new mechanism of leukemogenesis based on the altered nucleo-cytoplasmic trafficking of NPM1 (a nucleolar protein) but successfully built on his findings to translate them into clinics, contributing to define a new leukemia category in the 2016-WHO classification of lympho-hemopoietic neoplasms and to demonstrate the value of NPM1 mutations in predicting outcome of AML patients and in monitoring of minimal residual disease. At present, his work is focused to understand how the NPM1 mutant causes leukemogenesis and in translating this information to develop new anti-leukemic agents.

In 2011, his group also discovered the BRAF-V600E mutation as the causal genetic event of hairy cell leukemia, which leads to transformation through the constitutive activation of the MAPK pathway. Dr. Falini's group rapidly translated this landmark discovery from bench to the bedside, by setting up the first molecular diagnostic assay for hairy cell leukemia and demonstrating the clinical activity of the BRAF inhibitor vemurafenib (alone or in combination with an anti-CD20 monoclonal antibody) in patients with refractory/relapsed hairy cell leukemia.

He has received many awards, including The "Jose' Carreras Award" from the European Society of Hematology (EHA) in 2010, the "Leopold Griffuel Prize" in translational medicine from the French Association for Cancer Research (ARC) in 2015, the prize for "Excellence in Medicine" from the American Italian Cancer Foundation (AICF) in 2017, and the Henry Stratton Medal from ASH in 2018.